EcoDrugPlus

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha

Ensembl ID : ENSAOCG00000002675
Gene Symbol: LOC111582380
3 Cross references
203 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha-Like

Ensembl ID : ENSAOCG00000020448
Gene Symbol: LOC111569137
3 Cross references
197 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSAOCG00000018022
Gene Symbol: PIK3CA
3 Cross references
201 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSAOCG00000024294
Gene Symbol: PIK3CA
4 Cross references
194 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSAOCG00000001740
Gene Symbol: PIK3CB
3 Cross references
217 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSAOCG00000014660
Gene Symbol: PIK3CD
3 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSAOCG00000002034
Gene Symbol: PIK3CG
3 Cross references
216 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSAOCG00000003564
Gene Symbol: PDE10A
3 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSAOCG00000017356
Gene Symbol: PDE3A
3 Cross references
203 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSAOCG00000002695
Gene Symbol: PDE3A
4 Cross references
184 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSAOCG00000002938
Gene Symbol: PDE3B
3 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSAOCG00000005111
Gene Symbol: PDE4A
3 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).